All In Biotech

Drug Trial Radar · NCT04018027

Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Subjects With Atopic Dermatitis

A Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Oral Difelikefalin (CR845) for Moderate to Severe Pruritus in Adult Subjects With Atopic Dermatitis

Last checked: Nov 19, 2026Latest source record: Apr 4, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 401 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

401

Actual

Start

Jun 29, 2019

Primary completion

Apr 1, 2021

Study completion Apr 1, 2021

Sponsor

Lead sponsor
Cara Therapeutics, Inc.Industry
Sponsor type
Industry
First posted
Jul 12, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 80 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a multicenter, randomized, double-blind, 4-arm, placebo-controlled study to evaluate the efficacy and safety of twice-daily (BID) oral difelikefalin (CR845) in adult subjects with atopic dermatitis (AD) and moderate to severe pruritus.

Conditions

  • Pruritus
  • Atopic Dermatitis

Interventions

  • difelikefalin 0.25 mgDrug

    Oral difelikefalin 0.25 mg administered twice daily

  • difelikefalin 0.5 mgDrug

    Oral difelikefalin 0.5 mg administered twice daily

  • difelikefalin 1.0 mgDrug

    Oral difelikefalin 1.0 mg administered twice daily

  • PlaceboDrug

    Oral Placebo administered twice daily

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change from baseline in the weekly mean of the daily 24-hour Itch-Numeric Rating Scale (I-NRS) score at Week 12.Time frame: Baseline, Week 12

Locations

40 sites in 2 countries. Site status is shown where the registry gives one.

  • Cara Therapeutics Study Site

    Anniston, Alabama

  • Cara Therapeutics Study Site

    Birmingham, Alabama

  • Cara Therapeutics Study Site

    Scottsdale, Arizona

  • Cara Therapeutics Study Site

    Bryant, Arkansas

  • Cara Therapeutics Study Site

    Fountain Valley, California

  • Cara Therapeutics Study Site

    Lomita, California

  • Cara Therapeutics Study Site

    Cromwell, Connecticut

  • Cara Therapeutics Study Site

    Farmington, Connecticut

  • Cara Therapeutics Study Site

    Aventura, Florida

  • Cara Therapeutics Study Site 2

    Miami, Florida

  • Cara Therapeutics Study Site

    Miami, Florida

  • Cara Therapeutics Study Site

    Miami Lakes, Florida

  • Cara Therapeutics Study Site

    Ocala, Florida

  • Cara Therapeutics Study Site

    Sarasota, Florida

  • Cara Therapeutics Study Site

    Sweetwater, Florida

  • Cara Therapeutics Study Site

    Columbus, Georgia

  • Cara Therapeutics Study Site

    Boise, Idaho

  • Cara Therapeutics Study Site 2

    Boise, Idaho

  • Cara Therapeutics Study Site

    Baton Rouge, Louisiana

  • Cara Therapeutics Study Site

    Metairie, Louisiana

  • Cara Therapeutics Study Site

    New Orleans, Louisiana

  • Cara Therapeutics Study Site

    Brighton, Massachusetts

  • Cara Therapeutics Study Site 2

    Las Vegas, Nevada

  • Cara Therapeutics Study Site

    Berlin, New Jersey

  • Cara Therapeutics Study Site

    Horseheads, New York

  • Cara Therapeutics Study Site

    New York, New York

  • Cara Therapeutics Study Site

    New York, New York

  • Cara Therapeutics Study Site

    Cleveland, Ohio

  • Cara Therapeutics Study Site

    Oklahoma City, Oklahoma

  • Cara Therapeutics Study Site

    Tulsa, Oklahoma

  • Cara Therapeutics Study Site

    Medford, Oregon

  • Cara Therapeutics Study Site

    Rapid City, South Dakota

  • Cara Therapeutics Study Site 2

    Austin, Texas

  • Cara Therapeutics Study Site

    Austin, Texas

  • Cara Therapeutics Study Site

    Cypress, Texas

  • Cara Therapeutics Study Site

    Dallas, Texas

  • Cara Therapeutics Study Site

    Salt Lake City, Utah

  • Cara Therapeutics Study Site

    Richmond, Virginia

  • Cara Therapeutics Study Site

    London, Ontario, Canada

  • Cara Therapeutics Study Site

    Montreal, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.